Christine Helman

Christine E. Helman serves as a key procurement lead within the Army Medical Resources Acquisition Activity under the Defense Health Agency, where she oversees the acquisition of advanced biomedical research capabilities and clinical technology to sustain military medical readiness. Her work centers on securing cutting-edge biotechnology solutions, diagnostic instrumentation, and life sciences infrastructure critical to Army health operations. She manages complex contract actions aligned with the agency’s strategic priorities in biomedical innovation, ensuring that acquisitions support high-performance analytical systems and laboratory modernization initiatives across the defense health enterprise. Helman maintains strong, ongoing relationships with a select group of specialized contractors, including CHENEGA Professional & Technical Services LLC, SNA International LLC, MABEAL GmbH, Canon Medical Informatics Inc., and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. These partnerships reflect a preference for firms with deep expertise in military-relevant biotechnology, medical informatics, and research support services. Her contracting patterns emphasize long-term, performance-based collaborations with vendors capable of delivering integrated scientific solutions and technical innovation tailored to DoD medical requirements. Her procurement strategy is uniformly dedicated to small business participation, with 100% of her acquisitions structured as total small business set-asides under FAR 19.5. This reflects a deliberate and consistent commitment to fostering innovation through small business engagement, ensuring that emerging capabilities from niche providers are integrated into the military’s medical research and development pipeline. Helman’s portfolio is dominated by NAICS 541714 (Research and Development in Biotechnology), where she procures molecular diagnostics, genomic tools, and advanced therapeutic development services. She also supports NAICS 325199 for specialized organic chemical manufacturing critical to medical countermeasures and lab reagents. Her technical expertise lies at the intersection of biomedical R&D and operational medicine, ensuring acquisitions directly enhance the readiness and resilience of U.S. Army medical forces.